Global Benign Prostatic Hyperplasia Testing Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 93

Report ID: 1771

Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of the prostate doubles and the second growth phase starts at 25 years and continues throughout the lifetime. While the prostate gland enlarges in a man, it presses and pinches the urethra making the bladder wall thick. This pressure and squeeze on the urethra weaken the bladder and makes it lose the ability to empty the urine completely. Urinary retention and narrowing of the urethra can cause many problems which are associated with benign prostatic hyperplasia. Benign prostatic hyperplasia is one of the common prostate problems for men older than age 50.
Benign prostatic hyperplasia testing market is primarily driven by a few key factors such as the growing geriatric male population, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure, increasing government initiatives and availability of minimally invasive surgery as a drug replacement, faster and easy performing diagnosis test results. The market is likely to grow owing to the novel diagnostic methods which are accurate than the conventional PSA blood test for benign prostatic hyperplasia which is effective in diagnosis and is expected to fuel the growth of benign prostatic hyperplasia testing market.
However, faces various challenges such as researchers which have found new ways to prevent the disease. Benign prostatic hyperplasia testing market tests are still in the primary stages of development which is a major restraint for the market. Benign Prostatic Hyperplasia Testing Market faces tremendous challenges due to the low awareness regarding the various diseases and diagnostic measures. Low-income countries and rising economies are coming forward to address such issues for benign prostatic hyperplasia testing market.
In 2018, the global Benign Prostatic Hyperplasia Testing market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Benign Prostatic Hyperplasia Testing status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostatic Hyperplasia Testing development in United States, Europe and China.

The key players covered in this study
AEternaZentaris
Astellas Pharma
Eli Lilly and Company
IntelGenx Technologies Corp
Nymox Pharmaceutical Corporation
Protox Therapeutics
Quest PharmaTech
...

Market segment by Type, the product can be split into
Urinalysis
Prostate-Specific Antigen (PSA) Blood Test
Urodynamic Test
Cystoscopy

Market segment by Application, split into
Hospitals
Diagnostic Centers
Clinics
Research Institutes

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Benign Prostatic Hyperplasia Testing status, future forecast, growth opportunity, key market and key players.
To present the Benign Prostatic Hyperplasia Testing development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia Testing are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Benign Prostatic Hyperplasia Testing Market Size Growth Rate by Type (2014-2025)
1.4.2 Urinalysis
1.4.3 Prostate-Specific Antigen (PSA) Blood Test
1.4.4 Urodynamic Test
1.4.5 Cystoscopy
1.5 Market by Application
1.5.1 Global Benign Prostatic Hyperplasia Testing Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Diagnostic Centers
1.5.4 Clinics
1.5.5 Research Institutes
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Benign Prostatic Hyperplasia Testing Market Size
2.2 Benign Prostatic Hyperplasia Testing Growth Trends by Regions
2.2.1 Benign Prostatic Hyperplasia Testing Market Size by Regions (2014-2025)
2.2.2 Benign Prostatic Hyperplasia Testing Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Benign Prostatic Hyperplasia Testing Market Size by Manufacturers
3.1.1 Global Benign Prostatic Hyperplasia Testing Revenue by Manufacturers (2014-2019)
3.1.2 Global Benign Prostatic Hyperplasia Testing Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Benign Prostatic Hyperplasia Testing Market Concentration Ratio (CR5 and HHI)
3.2 Benign Prostatic Hyperplasia Testing Key Players Head office and Area Served
3.3 Key Players Benign Prostatic Hyperplasia Testing Product/Solution/Service
3.4 Date of Enter into Benign Prostatic Hyperplasia Testing Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Benign Prostatic Hyperplasia Testing Market Size by Type (2014-2019)
4.2 Global Benign Prostatic Hyperplasia Testing Market Size by Application (2014-2019)

5 United States
5.1 United States Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
5.2 Benign Prostatic Hyperplasia Testing Key Players in United States
5.3 United States Benign Prostatic Hyperplasia Testing Market Size by Type
5.4 United States Benign Prostatic Hyperplasia Testing Market Size by Application

6 Europe
6.1 Europe Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
6.2 Benign Prostatic Hyperplasia Testing Key Players in Europe
6.3 Europe Benign Prostatic Hyperplasia Testing Market Size by Type
6.4 Europe Benign Prostatic Hyperplasia Testing Market Size by Application

7 China
7.1 China Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
7.2 Benign Prostatic Hyperplasia Testing Key Players in China
7.3 China Benign Prostatic Hyperplasia Testing Market Size by Type
7.4 China Benign Prostatic Hyperplasia Testing Market Size by Application

8 Japan
8.1 Japan Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
8.2 Benign Prostatic Hyperplasia Testing Key Players in Japan
8.3 Japan Benign Prostatic Hyperplasia Testing Market Size by Type
8.4 Japan Benign Prostatic Hyperplasia Testing Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
9.2 Benign Prostatic Hyperplasia Testing Key Players in Southeast Asia
9.3 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Type
9.4 Southeast Asia Benign Prostatic Hyperplasia Testing Market Size by Application

10 India
10.1 India Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
10.2 Benign Prostatic Hyperplasia Testing Key Players in India
10.3 India Benign Prostatic Hyperplasia Testing Market Size by Type
10.4 India Benign Prostatic Hyperplasia Testing Market Size by Application

11 Central & South America
11.1 Central & South America Benign Prostatic Hyperplasia Testing Market Size (2014-2019)
11.2 Benign Prostatic Hyperplasia Testing Key Players in Central & South America
11.3 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Type
11.4 Central & South America Benign Prostatic Hyperplasia Testing Market Size by Application

12 International Players Profiles
12.1 AEternaZentaris
12.1.1 AEternaZentaris Company Details
12.1.2 Company Description and Business Overview
12.1.3 Benign Prostatic Hyperplasia Testing Introduction
12.1.4 AEternaZentaris Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.1.5 AEternaZentaris Recent Development
12.2 Astellas Pharma
12.2.1 Astellas Pharma Company Details
12.2.2 Company Description and Business Overview
12.2.3 Benign Prostatic Hyperplasia Testing Introduction
12.2.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.2.5 Astellas Pharma Recent Development
12.3 Eli Lilly and Company
12.3.1 Eli Lilly and Company Company Details
12.3.2 Company Description and Business Overview
12.3.3 Benign Prostatic Hyperplasia Testing Introduction
12.3.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.3.5 Eli Lilly and Company Recent Development
12.4 IntelGenx Technologies Corp
12.4.1 IntelGenx Technologies Corp Company Details
12.4.2 Company Description and Business Overview
12.4.3 Benign Prostatic Hyperplasia Testing Introduction
12.4.4 IntelGenx Technologies Corp Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.4.5 IntelGenx Technologies Corp Recent Development
12.5 Nymox Pharmaceutical Corporation
12.5.1 Nymox Pharmaceutical Corporation Company Details
12.5.2 Company Description and Business Overview
12.5.3 Benign Prostatic Hyperplasia Testing Introduction
12.5.4 Nymox Pharmaceutical Corporation Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.5.5 Nymox Pharmaceutical Corporation Recent Development
12.6 Protox Therapeutics
12.6.1 Protox Therapeutics Company Details
12.6.2 Company Description and Business Overview
12.6.3 Benign Prostatic Hyperplasia Testing Introduction
12.6.4 Protox Therapeutics Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.6.5 Protox Therapeutics Recent Development
12.7 Quest PharmaTech
12.7.1 Quest PharmaTech Company Details
12.7.2 Company Description and Business Overview
12.7.3 Benign Prostatic Hyperplasia Testing Introduction
12.7.4 Quest PharmaTech Revenue in Benign Prostatic Hyperplasia Testing Business (2014-2019)
12.7.5 Quest PharmaTech Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details